ORAGENICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.03 USD | -2.83% |
|
-8.85% | -81.69% |
| 12/04 | North American Morning Briefing : Big Banks Kick -2- | DJ |
| 29/03 | Oragenics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2022 | 0.13 10.98 | Sales 2023 | 0.04 3.14 | Capitalization | 14.46M 1.21B |
|---|---|---|---|---|---|
| Net income 2022 | -14M -1.17B | Net income 2023 | -20M -1.67B | EV / Sales 2022 | 1,18,42,208 x |
| Net cash position 2022 | 10.8M 901M | Net cash position 2023 | 3.16M 264M | EV / Sales 2023 | 29,99,79,895 x |
| P/E ratio 2022 |
-0.89
x | P/E ratio 2023 |
-0.61
x | Employees | 5 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 76.77% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -2.83% | ||
| 1 week | -8.85% | ||
| Current month | -28.47% | ||
| 1 month | -28.47% | ||
| 3 months | -78.54% | ||
| 6 months | -69.44% | ||
| Current year | -81.69% |
1 week
1.01
1.15
1 month
1.011.49
Current year
1.017.74
1 year
1.017.74
3 years
1.0169.00
5 years
1.01125.40
10 years
1.012 322.00
| Managers | Title | Age | Since |
|---|---|---|---|
Joseph Redmond
CEO | Chief Executive Officer | 64 | 28/12 |
Janet Huffman
DFI | Director of Finance/CFO | 52 | 07/23/07 |
Kimberly Murphy
BRD | Director/Board Member | 62 | 01/20/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Charles Pope
CHM | Chairman | 73 | 04/10/04 |
John Gandolfo
BRD | Director/Board Member | 63 | 04/23/04 |
Robert Koski
BRD | Director/Board Member | 65 | 30/09/30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 1.03 | -2.83% | 43,816 |
| 25/24/25 | 1.06 | -2.75% | 61,782 |
| 24/24/24 | 1.09 | 0.00% | 9,186 |
| 23/24/23 | 1.09 | +2.83% | 18,832 |
| 22/24/22 | 1.06 | -6.19% | 15,021 |
Delayed Quote Nyse, April 27, 2024 at 01:40 am IST
More quotes
Oragenics, Inc. is a development-stage company. It is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. It is focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for treating Niemann Pick Disease Type C (NPC), and proprietary powder formulation and an intranasal delivery device. Its lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. It is also focused on developing medical products that treat brain related illnesses and diseases (the Neurology Assets). Its lead product and focus is on the development and commercialization of ONP-002 for the treatment of mTBI.
Calendar
13/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -81.69% | 4.62M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +0.64% | 22.15B | |
| -17.37% | 21.02B | |
| -8.19% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- OGEN Stock
